Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Lifirafenib |
Trade Name | |
Synonyms | BGB-283 |
Drug Descriptions |
Lifirafenib (BGB-283) is a dual RAF kinase and EGFR inhibitor, which may lead to decreased tumor cell proliferation and reduced growth of tumors with activation of BRAF and/or EGFR (PMID: 26208524, PMID: 32182156). |
DrugClasses | BRAF Inhibitor 25 EGFR Inhibitor (Pan) 62 |
CAS Registry Number | 1446090-79-4 |
NCIT ID | C124995 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cetuximab + Lifirafenib | Cetuximab Lifirafenib | 1 | 0 |
Lifirafenib | Lifirafenib | 12 | 1 |
Lifirafenib + MK-8353 | Lifirafenib MK-8353 | 2 | 0 |
Lifirafenib + PD-0325901 | Lifirafenib PD-0325901 | 3 | 1 |
Lifirafenib + Pimasertib | Lifirafenib Pimasertib | 1 | 0 |
Lifirafenib + SCH772984 | Lifirafenib SCH772984 | 3 | 0 |
Lifirafenib + Selumetinib | Lifirafenib Selumetinib | 0 | 0 |
Lifirafenib + Trametinib | Lifirafenib Trametinib | 4 | 0 |
Lifirafenib + Ulixertinib | Lifirafenib Ulixertinib | 2 | 0 |
Lifirafenib + Vemurafenib | Lifirafenib Vemurafenib | 2 | 0 |